SS Innovations International, Inc (SSII)

SS Innovations International, Inc. (SSII) stock has experienced volatility, with its 52-week range spanning from $3.02 to $22.42. As of January 17, 2026, the 90-day share price return showed a 39.12% decline, and the 1-year total shareholder return was down 30.64%, although recent enthusiasm for the stock has begun to rebuild. In February 2026, the company filed for a $50 million share offering. In January 2026, SS Innovations reported preliminary unaudited revenue for the fourth quarter and full year 2025, projecting approximately $15.0 million for Q4 2025 and about $43.0 million for the full year 2025, with SSi Mantra installations also significantly increased. In January 2026, the company announced the appointment of Milan Rao as Global Chief Operating Officer and Chief Financial Officer. In January 2026, SS Innovations completed the development of five new 5-millimeter surgical instruments for robotic procedures. In December 2025, SS Innovations submitted its 510(k) premarket notification to the FDA for the SSi Mantra surgical robotic system.

Based on available information, there is no explicit indication of significant demand seasonality for SS Innovations International, Inc.'s products and services. The company has reported consistent and strong growth in revenue and system installations across different quarters and years, suggesting a steady increase in market demand for its surgical robotics solutions rather than seasonal fluctuations. The company's strategic focus on democratizing access to advanced surgical robotics and expanding into new global markets also points towards a continuous demand driver.

SS Innovations International, Inc. is a commercial-stage surgical robotics company focused on making advanced surgical robotics technologies more accessible and affordable globally. The company operates in the Healthcare sector, specifically in the Medical Devices industry. It designs, manufactures, and markets the SSi Mantra, an advanced surgical robotic system used for various soft-tissue, robotically assisted surgeries, including cardiac surgery. The company also produces instruments and accessories and provides installation, repair, maintenance, technical support, and system health monitoring services.

SS Innovations International, Inc. generates the majority of its revenue from India, where it has an established presence. The company's surgical robotic systems are approved for use in several other countries, including Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Ukraine, and Sri Lanka. SS Innovations is actively pursuing global expansion, with plans to enter the European and United States markets, anticipating U.S. FDA review and EU CE Mark certification in the first half of 2026. As of September 30, 2025, the SSi Mantra had a cumulative installed base of 125 systems across six countries, with over 6,000 surgical procedures performed.

SS Innovations International, Inc. has maintained a positive brand reputation, largely driven by its mission to make robotic surgery affordable and accessible. The company has demonstrated significant revenue growth and an increasing number of SSi Mantra system installations, with over 4,000 surgeries performed using the SSi Mantra system having zero reported device-related mortality, injuries, or complications. Dr. Frederic Moll joined SSII's board of directors as vice chairman, lending significant credibility to the company. The launch of SSi Mantra 3 and the continuous development of new instruments further enhance its reputation for innovation. The company's successful uplisting to NASDAQ and ongoing efforts to secure FDA and CE Mark approvals contribute to its growing international standing.

SS Innovations International, Inc. has 19 institutional owners and shareholders, collectively holding 359,409 shares. Major institutional shareholders include Handelsbanken Fonder AB, UBS Group AG, Forum Financial Management, LP, CWM Advisors, LLC, Geode Capital Management, Llc, AlTi Global, Inc., State Street Corp, Mariner, LLC, Envestnet Asset Management Inc, and Pnc Financial Services Group, Inc. Insider transactions have also been reported, with both buying and selling activity from individuals such as Sudhir Srivastava and Barry Cohen.